Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06807437 · ClinicalTrials.gov registry record · Phase 3
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
A Phase 3 study of Pancreatic Carcinoma and Pancreatic Neoplasm, sponsored by SWOG Cancer Research Network.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 274
- Enrollment target
- 20
- Study locations
NCT06807437 is a Phase 3 study of Pancreatic Carcinoma and Pancreatic Neoplasm that is actively recruiting participants, run by SWOG Cancer Research Network. The registered enrollment target is 274 participants, below the 3,469-participant average among 18 other Pancreatic Carcinoma trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT06807437, a Phase 3 study of Pancreatic Carcinoma and Pancreatic Neoplasm, is actively recruiting participants, sponsored by SWOG Cancer Research Network.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 274 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Saline
- OTHER Questionnaire Administration
- PROCEDURE Distal Pancreatectomy
- DRUG Lanreotide
Study Locations (20)
Illinois
- Northwestern University - Chicago
- University of Illinois - Chicago
- Northwestern Medicine Cancer Center Delnor - Geneva
- Northwestern Medicine Oak Brook - Oak Brook
- Northwestern Medicine Orland Park - Orland Park
- Northwestern Medicine Cancer Center Warrenville - Warrenville
Delaware
- Helen F Graham Cancer Center - Newark
- Medical Oncology Hematology Consultants PA - Newark
- Christiana Care Health System-Christiana Hospital - Newark
- Christiana Care Health System-Wilmington Hospital - Wilmington
Georgia
- Grady Health System - Atlanta
- Emory University Hospital Midtown - Atlanta
- Emory University Hospital/Winship Cancer Institute - Atlanta
- Emory Saint Joseph's Hospital - Atlanta
California
- UC San Diego Moores Cancer Center - La Jolla
- USC / Norris Comprehensive Cancer Center - Los Angeles
- UC San Diego Medical Center - Hillcrest - San Diego
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
- Mobile Infirmary Medical Center - Mobile
Indiana
- Indiana University/Melvin and Bren Simon Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2025-05-09 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06807437
The ClinicalTrials.gov registry entry for NCT06807437 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,469-participant average among 18 other Pancreatic Carcinoma trials with a reported enrollment target (92% lower). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pancreatic Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06807437 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Illinois, Delaware, Georgia.
Frequently Asked Questions
What is clinical trial NCT06807437 about?
NCT06807437 is a clinical study titled "Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula". This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by t...
What is the current status of trial NCT06807437?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 274 participants. The study started on 2025-05-09. Estimated completion is 2027-11-01.
What conditions does trial NCT06807437 study?
This clinical trial studies the following conditions: Pancreatic Carcinoma, Pancreatic Neoplasm.
What interventions are being tested in trial NCT06807437?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Saline (OTHER), Questionnaire Administration (OTHER), Distal Pancreatectomy (PROCEDURE), Lanreotide (DRUG).
Who is sponsoring clinical trial NCT06807437?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06807437 being conducted?
This trial has 20 study locations across Alabama, California, Delaware, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
RECRUITING
-
Pilot Study of Pancreatic Cancer Screening
RECRUITING
-
Use Of Indocyanine Green In Pancreas Surgery
RECRUITING
-
A Study of MGC028 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Pancreatic Cancer Detection Consortium
RECRUITING
-
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.